Before testing the clinical samples using our mutant primer sets to detect the G12D and G13D KRAS mutations, basic experiments were performed using genomic DNA obtained from 2 cancer cell lines, including AGS cells (which carry a G12D mutation but no G13D mutation) and HCT116 cells (which carry a G13D mutation but no G12D mutation). This evidence concerns the gene KRAS and cancer.